Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma

Sota Oguro, Subaru Hashimoto, Tomoaki Tanaka, Masanori Inoue, Seishi Nakatsuka, Sachio Kuribayashi, Keiko Asakura, Shigeyuki Kawachi, Minoru Tanabe, Yuukou Kitagawa, Hirotoshi Ebinuma, Hidetsugu Saito, Toshifumi Hibi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To retrospectively investigate the short-term therapeutic effects and adverse effects associated with the use of miriplatin-lipiodol suspension for transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), using TACE with cisplatin-lipiodol suspension as the historical control. Materials and methods: The study was conducted on 48 and 50 consecutive patients with HCC who underwent TACE with miriplatin-lipiodol suspension and cisplatin-lipiodol suspension, respectively. Therapeutic effect was evaluated by mRECIST. Adverse effects were graded by CTCAE, version 4.0. The therapeutic and adverse effects were compared using Fisher's exact test and multivariate logistic regression. Results: Complete remission, partial response, stable disease and progressive disease were observed in 37.5, 18.8, 33.3 and 10.4 % of patients in the miriplatin group, with the corresponding percentages being 54.0, 32.0, 14.0 and 0.0 %, respectively, in the cisplatin group. The short-term therapeutic effects were statistically significantly worse in the miriplatin group than in the cisplatin group, even after adjustment for tumor size and Child-Pugh class. The rates of nausea and serum creatinine elevation were statistically significantly lower in the miriplatin group (p < 0.05). Conclusion: TACE using miriplatin-lipiodol suspension yielded worse short-term responses than cisplatin-lipiodol suspension; however, the rates of adverse events were significantly lower in the miriplatin group.

Original languageEnglish
Pages (from-to)735-742
Number of pages8
JournalJapanese Journal of Radiology
Volume30
Issue number9
DOIs
Publication statusPublished - 2012 Nov

Fingerprint

Ethiodized Oil
Therapeutic Uses
Hepatocellular Carcinoma
Suspensions
Cisplatin
miriplatin
Nausea
Creatinine
Logistic Models
Serum

Keywords

  • Cisplatin
  • Hepatocellular carcinoma
  • Miriplatin
  • Multivariate logistic regression
  • Transcatheter arterial chemoembolization

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma. / Oguro, Sota; Hashimoto, Subaru; Tanaka, Tomoaki; Inoue, Masanori; Nakatsuka, Seishi; Kuribayashi, Sachio; Asakura, Keiko; Kawachi, Shigeyuki; Tanabe, Minoru; Kitagawa, Yuukou; Ebinuma, Hirotoshi; Saito, Hidetsugu; Hibi, Toshifumi.

In: Japanese Journal of Radiology, Vol. 30, No. 9, 11.2012, p. 735-742.

Research output: Contribution to journalArticle

Oguro, Sota ; Hashimoto, Subaru ; Tanaka, Tomoaki ; Inoue, Masanori ; Nakatsuka, Seishi ; Kuribayashi, Sachio ; Asakura, Keiko ; Kawachi, Shigeyuki ; Tanabe, Minoru ; Kitagawa, Yuukou ; Ebinuma, Hirotoshi ; Saito, Hidetsugu ; Hibi, Toshifumi. / Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma. In: Japanese Journal of Radiology. 2012 ; Vol. 30, No. 9. pp. 735-742.
@article{c806233fa6e0448f82cd464aeeda4f72,
title = "Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma",
abstract = "Purpose: To retrospectively investigate the short-term therapeutic effects and adverse effects associated with the use of miriplatin-lipiodol suspension for transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), using TACE with cisplatin-lipiodol suspension as the historical control. Materials and methods: The study was conducted on 48 and 50 consecutive patients with HCC who underwent TACE with miriplatin-lipiodol suspension and cisplatin-lipiodol suspension, respectively. Therapeutic effect was evaluated by mRECIST. Adverse effects were graded by CTCAE, version 4.0. The therapeutic and adverse effects were compared using Fisher's exact test and multivariate logistic regression. Results: Complete remission, partial response, stable disease and progressive disease were observed in 37.5, 18.8, 33.3 and 10.4 {\%} of patients in the miriplatin group, with the corresponding percentages being 54.0, 32.0, 14.0 and 0.0 {\%}, respectively, in the cisplatin group. The short-term therapeutic effects were statistically significantly worse in the miriplatin group than in the cisplatin group, even after adjustment for tumor size and Child-Pugh class. The rates of nausea and serum creatinine elevation were statistically significantly lower in the miriplatin group (p < 0.05). Conclusion: TACE using miriplatin-lipiodol suspension yielded worse short-term responses than cisplatin-lipiodol suspension; however, the rates of adverse events were significantly lower in the miriplatin group.",
keywords = "Cisplatin, Hepatocellular carcinoma, Miriplatin, Multivariate logistic regression, Transcatheter arterial chemoembolization",
author = "Sota Oguro and Subaru Hashimoto and Tomoaki Tanaka and Masanori Inoue and Seishi Nakatsuka and Sachio Kuribayashi and Keiko Asakura and Shigeyuki Kawachi and Minoru Tanabe and Yuukou Kitagawa and Hirotoshi Ebinuma and Hidetsugu Saito and Toshifumi Hibi",
year = "2012",
month = "11",
doi = "10.1007/s11604-012-0116-1",
language = "English",
volume = "30",
pages = "735--742",
journal = "Japanese Journal of Radiology",
issn = "1867-1071",
publisher = "Springer Japan",
number = "9",

}

TY - JOUR

T1 - Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma

AU - Oguro, Sota

AU - Hashimoto, Subaru

AU - Tanaka, Tomoaki

AU - Inoue, Masanori

AU - Nakatsuka, Seishi

AU - Kuribayashi, Sachio

AU - Asakura, Keiko

AU - Kawachi, Shigeyuki

AU - Tanabe, Minoru

AU - Kitagawa, Yuukou

AU - Ebinuma, Hirotoshi

AU - Saito, Hidetsugu

AU - Hibi, Toshifumi

PY - 2012/11

Y1 - 2012/11

N2 - Purpose: To retrospectively investigate the short-term therapeutic effects and adverse effects associated with the use of miriplatin-lipiodol suspension for transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), using TACE with cisplatin-lipiodol suspension as the historical control. Materials and methods: The study was conducted on 48 and 50 consecutive patients with HCC who underwent TACE with miriplatin-lipiodol suspension and cisplatin-lipiodol suspension, respectively. Therapeutic effect was evaluated by mRECIST. Adverse effects were graded by CTCAE, version 4.0. The therapeutic and adverse effects were compared using Fisher's exact test and multivariate logistic regression. Results: Complete remission, partial response, stable disease and progressive disease were observed in 37.5, 18.8, 33.3 and 10.4 % of patients in the miriplatin group, with the corresponding percentages being 54.0, 32.0, 14.0 and 0.0 %, respectively, in the cisplatin group. The short-term therapeutic effects were statistically significantly worse in the miriplatin group than in the cisplatin group, even after adjustment for tumor size and Child-Pugh class. The rates of nausea and serum creatinine elevation were statistically significantly lower in the miriplatin group (p < 0.05). Conclusion: TACE using miriplatin-lipiodol suspension yielded worse short-term responses than cisplatin-lipiodol suspension; however, the rates of adverse events were significantly lower in the miriplatin group.

AB - Purpose: To retrospectively investigate the short-term therapeutic effects and adverse effects associated with the use of miriplatin-lipiodol suspension for transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), using TACE with cisplatin-lipiodol suspension as the historical control. Materials and methods: The study was conducted on 48 and 50 consecutive patients with HCC who underwent TACE with miriplatin-lipiodol suspension and cisplatin-lipiodol suspension, respectively. Therapeutic effect was evaluated by mRECIST. Adverse effects were graded by CTCAE, version 4.0. The therapeutic and adverse effects were compared using Fisher's exact test and multivariate logistic regression. Results: Complete remission, partial response, stable disease and progressive disease were observed in 37.5, 18.8, 33.3 and 10.4 % of patients in the miriplatin group, with the corresponding percentages being 54.0, 32.0, 14.0 and 0.0 %, respectively, in the cisplatin group. The short-term therapeutic effects were statistically significantly worse in the miriplatin group than in the cisplatin group, even after adjustment for tumor size and Child-Pugh class. The rates of nausea and serum creatinine elevation were statistically significantly lower in the miriplatin group (p < 0.05). Conclusion: TACE using miriplatin-lipiodol suspension yielded worse short-term responses than cisplatin-lipiodol suspension; however, the rates of adverse events were significantly lower in the miriplatin group.

KW - Cisplatin

KW - Hepatocellular carcinoma

KW - Miriplatin

KW - Multivariate logistic regression

KW - Transcatheter arterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=84877059903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877059903&partnerID=8YFLogxK

U2 - 10.1007/s11604-012-0116-1

DO - 10.1007/s11604-012-0116-1

M3 - Article

VL - 30

SP - 735

EP - 742

JO - Japanese Journal of Radiology

JF - Japanese Journal of Radiology

SN - 1867-1071

IS - 9

ER -